NitroMed lays off researchers in shakeup

Reeling from low sales of its newly-approved heart drug BiDil, NitroMed has announced it is laying off 30 researchers and is looking for partners for other experimental heart therapies in its pipeline. The Lexington, MA-based company's CEO and CFO had already been let go earlier this month, and NitroMed is focusing its efforts on gearing up sales of BiDil. About 150 contract sales people are being made full time employees.

- read the Boston Herald report

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.